Researchers at Queen Mary University of London have led the clinical development of the first non-integrase strand-transfer ...
The U.S. Food and Drug Administration has approved Yuvezzi (carbachol and brimonidine tartrate) ophthalmic solution 2.75%/0.1 ...
In July 2025, 3 4DMT announced its intent to accelerate its 4D-150 4FRONT phase 3 program in wet AMD and lay off approximately 25% of staff. 4DMT noted that this transition supported the company’s ...
Menopause clinics across the U.S. are hearing from women who are having trouble filling prescriptions for estrogen patches, a common hormone replacement therapy.
Ocular Therapeutix (OCUL) is a Strong Buy, driven by the pivotal SOL-1 Phase 3 trial for AXPAXLI™ in wet AMD, with topline ...
The 2028 negotiation cycle marks another major inflection point in the implementation of the Medicare Drug Price Negotiation Program—its first year incorporating Part B drugs and its first opportunity ...
Combination antiretroviral therapy (ART) has transformed HIV-1 infection into a chronic condition with near-normal life expectancy. For more than two decades, the standard regimen has been a ...
BWX Technologies says its TRISO nuclear fuel for Antares Nuclear is on track for "timely completion" for the reactor demonstration planned to meet the US’s 4 July target date. ; ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results